Back to results
US 2010/0247531 A1Published application
Anti-fgfr3 antibodies and methods using same
AssigneeGenentech, Inc.
InventorsAvi Ashkenazi, Jing Qing, Christian Wiesmann, Yan Wu
Life of this patent
Estimating the term…
Abstract
The invention provides FGFR3 antibodies, and compositions comprising and methods of using these antibodies.
Claims59
An isolated anti-FGFR3 antagonist antibody, where the antibody binds human FGFR3 with a Kd of 1×10−8 or stronger, and wherein the antibody inhibits dimerization of FGFR3 receptor with another unit of the receptor, whereby activation of the receptor is inhibited.
An isolated anti-FGFR3 antagonist antibody, wherein the antibody comprises:
- (i) HVR-L3 comprising sequence QQX1X2X3X4X5X6T, wherein X1 is G, S or T, X2 is T, Y or A, X3 is G, S, T, or A, X4 is A, H, D, T, or N, X5 is Q, P or S, X6 is S, Y, L, P or Q (SEQ ID NO:148),
- (ii) HVR-H2 comprising sequence GRIYPX1X2X3X4X5X6YADSVKG, wherein X1 is Y, A, L, 5, or T, X2 is A, Q, D, G, Y, 5, N or F, X3 is A, D, or G, X4 is T or 5, X5 is K, F, T, or S, X6 is Y, H, N or I (SEQ ID NO:150), and
- (iii) HVR-H3 comprising sequence ARTYGIYDLYVDYTEYVMDY (SEQ ID NO:151), wherein the antibody specifically binds FGFR3.
An anti-FGFR3 antagonist antibody, wherein the antibody comprises:
- (i) HVR-L1 comprising sequence RASQX1X2X3X4X5 X6A, wherein X1 is V or D, X2 is V or I, X3 is D, E or S, X4 is T or I, X5 is A or S, and X6 is V or L (SEQ ID NO:146),
- (ii) HVR-L2 comprising sequence X1ASFLX2S wherein X1 is S or G and X2 is A or Y (SEQ ID NO:147), and
- (iii) HVR-L3 comprising sequence QQX1X2X3X4X5X6T, wherein X1 is G, S or T, X2 is T, Y or A, X3 is G, S, T, or A, X4 is A, H, D, T, or N, X5 is Q, P or S, X6 is S, Y, L, P or Q (SEQ ID NO:148), wherein the antibody specifically binds FGFR3.
An anti-FGFR3 antibody comprising:
- at least one, two, three, four, five, and/or six hypervariable region (HVR) sequences selected from the group consisting of:
- (a) HVR-L1 comprising sequence SASSSVSYMH (SEQ ID NO:155), SASSSVSYMH (SEQ ID NO:156) or LASQTIGTWLA (SEQ ID NO:157),
- (b) HVR-L2 comprising sequence TWIYDTSILAS (SEQ ID NO:158), RWIYDTSKLAS (SEQ ID NO:159), or LLIYAATSLAD (SEQ ID NO:160),
- (c) HVR-L3 comprising sequence QQWTSNPLT (SEQ ID NO:161), QQWSSYPPT (SEQ ID NO:162), or QQLYSPPWT (SEQ ID NO:163),
- (d) HVR-H1 comprising sequence GYSFTDYNMY (SEQ ID NO:164), GYVFTHYNMY (SEQ ID NO:165), or GYAFTSYNMY (SEQ ID NO:166),
- (e) HVR-H2 comprising sequence WIGYIEPYNGGTSYNQKFKG (SEQ ID NO:167), WIGYIEPYNGGTSYNQKFKG (SEQ ID NO:168), or WIGYIDPYIGGTSYNQKFKG (SEQ ID NO:169), and
- (f) HVR-H3 comprising sequence ASPNYYDSSPFAY (SEQ ID NO:170), ARGQGPDFDV (SEQ ID NO:171), or ARWGDYDVGAMDY (SEQ ID NO:172).
4 more elements
Dependencies are inferred from the claim text.